Fennec Announces Results of Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Fennec Pharmaceuticals (NASDAQ:FENC) held its Annual General and Special Meeting on June 3, 2025, in New York. All six nominated directors were successfully elected with strong shareholder support, receiving approval rates between 93.62% and 97.84%. Shareholders also approved key proposals including: the appointment of Haskell & White LLP as auditors (99.64% approval), executive compensation (85.50% approval), and amendments to the 2020 Equity Incentive Plan (91.27% approval, or 88.01% excluding insider shares). The company noted its reliance on TSX Company Manual Section 602.1 exemption for the equity plan amendments, applicable to Nasdaq-listed companies.
Fennec Pharmaceuticals (NASDAQ:FENC) ha tenuto la sua Assemblea Generale Annuale e Straordinaria il 3 giugno 2025 a New York. Tutti e sei i direttori nominati sono stati eletti con successo, ottenendo un forte sostegno degli azionisti, con tassi di approvazione compresi tra il 93,62% e il 97,84%. Gli azionisti hanno inoltre approvato proposte chiave, tra cui: la nomina di Haskell & White LLP come revisori contabili (99,64% di approvazione), la remunerazione dei dirigenti (85,50% di approvazione) e le modifiche al Piano di Incentivi Azionari 2020 (91,27% di approvazione, o 88,01% escludendo le azioni interne). La societ脿 ha sottolineato di aver fatto affidamento sull'esenzione della Sezione 602.1 del Manuale Aziendale TSX per le modifiche al piano azionario, applicabile alle societ脿 quotate al Nasdaq.
Fennec Pharmaceuticals (NASDAQ:FENC) celebr贸 su Junta General Anual y Extraordinaria el 3 de junio de 2025 en Nueva York. Los seis directores nominados fueron elegidos con 茅xito, recibiendo un fuerte apoyo de los accionistas con tasas de aprobaci贸n entre el 93,62% y el 97,84%. Los accionistas tambi茅n aprobaron propuestas clave, incluyendo: el nombramiento de Haskell & White LLP como auditores (99,64% de aprobaci贸n), la compensaci贸n ejecutiva (85,50% de aprobaci贸n) y las enmiendas al Plan de Incentivos de Acciones 2020 (91,27% de aprobaci贸n, o 88,01% excluyendo acciones internas). La compa帽铆a se帽al贸 su dependencia de la exenci贸n de la Secci贸n 602.1 del Manual de la Compa帽铆a TSX para las enmiendas del plan de acciones, aplicable a empresas listadas en Nasdaq.
Fennec Pharmaceuticals(NASDAQ:FENC)電� 2025雲� 6鞗� 3鞚� 雺挫殨鞐愳劀 鞐半 氚� 韸闺硠 欤检＜齑濏殞毳� 臧滌禍頄堨姷雼堧嫟. 歆�氇呺悳 6氇呾潣 鞚挫偓臧� 氇憪 靹标车鞝侅溂搿� 靹犾稖霅橃棃鞙茧┌, 欤检＜霌れ潣 臧曧暅 歆�歆�毳� 氚涭晞 鞀轨澑鞙潃 93.62%鞐愳劀 97.84% 靷澊鞓�鞀惦媹雼�. 欤检＜霌れ潃 霕愴暅 欤检殧 鞎堦贝霌れ潉 鞀轨澑頄堧姅雿�, 鞐赴鞐愲姅 Haskell & White LLP鞚� 臧愳偓鞚� 鞛勲獏(99.64% 鞀轨澑), 瓴届榿歆� 氤挫垬(85.50% 鞀轨澑), 2020雲� 欤检嫕 鞚胳劶韹半笇 瓿勴殟 靾橃爼鞎�(雮措秬 欤检嫕鞚� 鞝滌櫢頃� 瓴届毎 88.01%, 鞝勳泊 91.27% 鞀轨澑)鞚� 韽暔霅╇媹雼�. 須岇偓電� 雮橃姢雼� 靸侅灔 旮办梾鞐� 鞝侅毄霅橂姅 TSX 須岇偓 毵る壌鞏� 靹轨厴 602.1鞚� 氅挫牅毳� 欤检嫕 瓿勴殟 靾橃爼鞐� 鞚橃〈頄堧嫟瓿� 氚濏様鞀惦媹雼�.
Fennec Pharmaceuticals (NASDAQ:FENC) a tenu son Assembl茅e G茅n茅rale Annuelle et Extraordinaire le 3 juin 2025 脿 New York. Les six administrateurs propos茅s ont 茅t茅 茅lus avec succ猫s, b茅n茅ficiant d'un fort soutien des actionnaires, avec des taux d'approbation compris entre 93,62 % et 97,84 %. Les actionnaires ont 茅galement approuv茅 des propositions cl茅s, notamment : la nomination de Haskell & White LLP en tant qu'auditeurs (99,64 % d'approbation), la r茅mun茅ration des dirigeants (85,50 % d'approbation) et les modifications du Plan d'Incitation en Actions 2020 (91,27 % d'approbation, ou 88,01 % hors actions d茅tenues par les initi茅s). La soci茅t茅 a indiqu茅 s'appuyer sur l'exemption de la section 602.1 du Manuel de la Soci茅t茅 TSX pour les modifications du plan d'actions, applicable aux entreprises cot茅es au Nasdaq.
Fennec Pharmaceuticals (NASDAQ:FENC) hielt am 3. Juni 2025 in New York seine j盲hrliche Haupt- und Sonderversammlung ab. Alle sechs nominierten Direktoren wurden erfolgreich mit starker Aktion盲rsunterst眉tzung gew盲hlt, wobei die Zustimmungsraten zwischen 93,62 % und 97,84 % lagen. Die Aktion盲re genehmigten auch wichtige Vorschl盲ge, darunter die Ernennung von Haskell & White LLP als Wirtschaftspr眉fer (99,64 % Zustimmung), die Verg眉tung der Gesch盲ftsleitung (85,50 % Zustimmung) sowie 脛nderungen am Aktienanreizplan 2020 (91,27 % Zustimmung bzw. 88,01 % ohne Insider-Aktien). Das Unternehmen wies darauf hin, dass es bei den 脛nderungen des Aktienplans auf die Befreiung gem盲脽 Abschnitt 602.1 des TSX-Unternehmenshandbuchs vertraut, die f眉r an der Nasdaq gelistete Unternehmen gilt.
Positive
- High approval rates for all directors with over 93% support
- Strong shareholder support (99.64%) for auditor appointment
- Successful passage of all proposed amendments and compensation plans
Negative
- None.
RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the 鈥淐ompany鈥�) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 25, 2025 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held in New York, New York on June 3, 2025.
Detailed results of the vote for the election of directors are set out below:
| Name of Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
| Dr. Khalid Islam | 13,858,131 | 304,760 | ||
| Mr. Chris A. Rallis | 13,808,792 | 354,099 | ||
| Mr. Marco Brughera | 13,807,501 | 355,390 | ||
| Dr. Jodi Cook | 13,259,894 | 902,997 | ||
| Mr. Rostislav Raykov | 13,432,561 | 730,330 | ||
| Mr. Jeff Hackman | 13,495,309 | 667,582 |
Shareholders voted
The Company has relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq, in the approval of the amendments to its 2020 Equity Incentive Plan.
For further information, please contact:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
Tel: 919-246-5299
FAQ
Who are the directors elected to Fennec Pharmaceuticals (FENC) board in 2025?
The elected directors are Dr. Khalid Islam, Mr. Chris A. Rallis, Mr. Marco Brughera, Dr. Jodi Cook, Mr. Rostislav Raykov, and Mr. Jeff Hackman.
What was the voting result for Fennec Pharmaceuticals' 2020 Equity Incentive Plan amendments?
The amendments received 91.27% approval overall, and 88.01% approval after excluding shares held by insiders eligible to participate in the plan.
Who received the highest and lowest shareholder approval among Fennec's directors?
Dr. Khalid Islam received the highest approval at 97.84%, while Dr. Jodi Cook received the lowest at 93.62%.
What was the shareholder approval rate for Fennec's executive compensation?
Shareholders voted 85.50% in favor of the compensation paid to the company's named executive officers.
Fennec Pharmaceuticals Inc
NASDAQ:FENC
FENC Rankings
FENC Latest News
Aug 11, 2025
Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
May 13, 2025
Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
FENC Latest SEC Filings
Aug 5, 2025
[144] Fennec Pharmaceuticals Inc. SEC Filing
FENC Stock Data
225.37M
22.75M
16.26%
57.78%
4.72%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
RESEARCH TRIANGLE PARK